(DVA) DaVita HealthCare Partners - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US23918K1088
Stock: Dialysis, Laboratory, Management, Care, Transplant
Total Rating 39
Risk 68
Buy Signal -0.97
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 64.8% |
| Relative Tail Risk | -11.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.44 |
| Alpha | -28.97 |
| Character TTM | |
|---|---|
| Beta | 0.390 |
| Beta Downside | 0.190 |
| Drawdowns 3y | |
|---|---|
| Max DD | 41.43% |
| CAGR/Max DD | 0.47 |
Description: DVA DaVita HealthCare Partners January 02, 2026
DaVita Inc. (NYSE:DVA) is the largest U.S. provider of kidney dialysis services, operating a network of outpatient centers that deliver in-center, home-based, and hospital-based hemodialysis, along with associated laboratory and disease-management programs for patients with end-stage renal disease (ESRD).
In fiscal 2023 the company generated approximately $13.5 billion in revenue, maintained an adjusted EBITDA margin near 28 %, and served roughly 210,000 dialysis patients, with home-dialysis volumes expanding about 15 % year-over-year-a key growth lever as Medicare shifts reimbursement toward home-based care.
Key economic and sector drivers include the aging U.S. population (the 65-plus cohort is projected to reach 22 % of the population by 2035), rising chronic kidney disease prevalence, and ongoing Medicare policy reforms that tie reimbursement to quality and cost-efficiency metrics, all of which directly impact DaVita’s volume and margin outlook.
For a deeper quantitative assessment of DVA’s valuation metrics, the ValueRay platform offers a concise, data-driven dashboard worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 746.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.99 > 1.0 |
| NWC/Revenue: 6.72% < 20% (prev 6.03%; Δ 0.69% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.89b > Net Income 746.8m |
| Net Debt (14.29b) to EBITDA (2.64b): 5.41 < 3 |
| Current Ratio: 1.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.1m) vs 12m ago 2.69% < -2% |
| Gross Margin: 30.88% > 18% (prev 0.33%; Δ 3055 % > 0.5%) |
| Asset Turnover: 78.49% > 50% (prev 74.14%; Δ 4.35% > 0%) |
| Interest Coverage Ratio: 3.51 > 6 (EBITDA TTM 2.64b / Interest Expense TTM 549.7m) |
Altman Z'' 1.00
| A: 0.05 (Total Current Assets 4.06b - Total Current Liabilities 3.14b) / Total Assets 17.48b |
| B: -0.02 (Retained Earnings -328.4m / Total Assets 17.48b) |
| C: 0.11 (EBIT TTM 1.93b / Avg Total Assets 17.38b) |
| D: -0.03 (Book Value of Equity -451.1m / Total Liabilities 16.32b) |
| Altman-Z'' Score: 1.00 = BB |
Beneish M -2.88
| DSRI: 1.10 (Receivables 2.96b/2.53b, Revenue 13.64b/12.82b) |
| GMI: 1.07 (GM 30.88% / 32.91%) |
| AQI: 1.04 (AQ_t 0.47 / AQ_t-1 0.45) |
| SGI: 1.06 (Revenue 13.64b / 12.82b) |
| TATA: -0.07 (NI 746.8m - CFO 1.89b) / TA 17.48b) |
| Beneish M-Score: -2.88 (Cap -4..+1) = A |
What is the price of DVA shares?
As of February 09, 2026, the stock is trading at USD 140.83 with a total of 2,254,829 shares traded.
Over the past week, the price has changed by +26.66%, over one month by +25.08%, over three months by +17.19% and over the past year by -18.84%.
Over the past week, the price has changed by +26.66%, over one month by +25.08%, over three months by +17.19% and over the past year by -18.84%.
Is DVA a buy, sell or hold?
DaVita HealthCare Partners has received a consensus analysts rating of 3.10.
Therefor, it is recommend to hold DVA.
- StrongBuy: 1
- Buy: 0
- Hold: 8
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the DVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 145.9 | 3.6% |
| Analysts Target Price | 145.9 | 3.6% |
| ValueRay Target Price | 147.1 | 4.4% |
DVA Fundamental Data Overview February 05, 2026
P/E Trailing = 14.1672
P/E Forward = 10.6838
P/S = 0.7061
P/B = 21.6266
P/EG = 1.2873
Revenue TTM = 13.64b USD
EBIT TTM = 1.93b USD
EBITDA TTM = 2.64b USD
Long Term Debt = 10.18b USD (from longTermDebt, two quarters ago)
Short Term Debt = 534.7m USD (from shortTermDebt, last quarter)
Debt = 15.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.29b USD (from netDebt column, last quarter)
Enterprise Value = 23.90b USD (9.63b + Debt 15.05b - CCE 782.0m)
Interest Coverage Ratio = 3.51 (Ebit TTM 1.93b / Interest Expense TTM 549.7m)
EV/FCF = 18.24x (Enterprise Value 23.90b / FCF TTM 1.31b)
FCF Yield = 5.48% (FCF TTM 1.31b / Enterprise Value 23.90b)
FCF Margin = 9.61% (FCF TTM 1.31b / Revenue TTM 13.64b)
Net Margin = 5.47% (Net Income TTM 746.8m / Revenue TTM 13.64b)
Gross Margin = 30.88% ((Revenue TTM 13.64b - Cost of Revenue TTM 9.43b) / Revenue TTM)
Gross Margin QoQ = 28.28% (prev 31.80%)
Tobins Q-Ratio = 1.37 (Enterprise Value 23.90b / Total Assets 17.48b)
Interest Expense / Debt = 0.78% (Interest Expense 118.0m / Debt 15.05b)
Taxrate = 20.05% (76.7m / 382.8m)
NOPAT = 1.54b (EBIT 1.93b * (1 - 20.05%))
Current Ratio = 1.29 (Total Current Assets 4.06b / Total Current Liabilities 3.14b)
Debt / Equity = -23.12 (negative equity) (Debt 15.05b / totalStockholderEquity, last quarter -651.1m)
Debt / EBITDA = 5.41 (Net Debt 14.29b / EBITDA 2.64b)
Debt / FCF = 10.90 (Net Debt 14.29b / FCF TTM 1.31b)
Total Stockholder Equity = -464.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.30% (Net Income 746.8m / Total Assets 17.48b)
RoE = -160.6% (negative equity) (Net Income TTM 746.8m / Total Stockholder Equity -464.9m)
RoCE = 19.82% (EBIT 1.93b / Capital Employed (Equity -464.9m + L.T.Debt 10.18b))
RoIC = 15.92% (NOPAT 1.54b / Invested Capital 9.68b)
WACC = 3.25% (E(9.63b)/V(24.68b) * Re(7.35%) + D(15.05b)/V(24.68b) * Rd(0.78%) * (1-Tc(0.20)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -2.56%
[DCF Debug] Terminal Value 86.37% ; FCFF base≈1.37b ; Y1≈1.38b ; Y5≈1.47b
Fair Price DCF = 417.8 (EV 43.79b - Net Debt 14.29b = Equity 29.50b / Shares 70.6m; r=5.90% [WACC]; 5y FCF grow -0.16% → 2.90% )
EPS Correlation: 63.88 | EPS CAGR: 22.06% | SUE: 1.02 | # QB: 1
Revenue Correlation: 95.69 | Revenue CAGR: 6.91% | SUE: 2.87 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.47 | Chg30d=+0.008 | Revisions Net=+3 | Analysts=2
EPS current Year (2026-12-31): EPS=13.83 | Chg30d=+1.079 | Revisions Net=-1 | Growth EPS=+28.3% | Growth Revenue=+2.9%
EPS next Year (2027-12-31): EPS=15.72 | Chg30d=+0.793 | Revisions Net=+0 | Growth EPS=+13.7% | Growth Revenue=+3.5%
P/E Forward = 10.6838
P/S = 0.7061
P/B = 21.6266
P/EG = 1.2873
Revenue TTM = 13.64b USD
EBIT TTM = 1.93b USD
EBITDA TTM = 2.64b USD
Long Term Debt = 10.18b USD (from longTermDebt, two quarters ago)
Short Term Debt = 534.7m USD (from shortTermDebt, last quarter)
Debt = 15.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.29b USD (from netDebt column, last quarter)
Enterprise Value = 23.90b USD (9.63b + Debt 15.05b - CCE 782.0m)
Interest Coverage Ratio = 3.51 (Ebit TTM 1.93b / Interest Expense TTM 549.7m)
EV/FCF = 18.24x (Enterprise Value 23.90b / FCF TTM 1.31b)
FCF Yield = 5.48% (FCF TTM 1.31b / Enterprise Value 23.90b)
FCF Margin = 9.61% (FCF TTM 1.31b / Revenue TTM 13.64b)
Net Margin = 5.47% (Net Income TTM 746.8m / Revenue TTM 13.64b)
Gross Margin = 30.88% ((Revenue TTM 13.64b - Cost of Revenue TTM 9.43b) / Revenue TTM)
Gross Margin QoQ = 28.28% (prev 31.80%)
Tobins Q-Ratio = 1.37 (Enterprise Value 23.90b / Total Assets 17.48b)
Interest Expense / Debt = 0.78% (Interest Expense 118.0m / Debt 15.05b)
Taxrate = 20.05% (76.7m / 382.8m)
NOPAT = 1.54b (EBIT 1.93b * (1 - 20.05%))
Current Ratio = 1.29 (Total Current Assets 4.06b / Total Current Liabilities 3.14b)
Debt / Equity = -23.12 (negative equity) (Debt 15.05b / totalStockholderEquity, last quarter -651.1m)
Debt / EBITDA = 5.41 (Net Debt 14.29b / EBITDA 2.64b)
Debt / FCF = 10.90 (Net Debt 14.29b / FCF TTM 1.31b)
Total Stockholder Equity = -464.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.30% (Net Income 746.8m / Total Assets 17.48b)
RoE = -160.6% (negative equity) (Net Income TTM 746.8m / Total Stockholder Equity -464.9m)
RoCE = 19.82% (EBIT 1.93b / Capital Employed (Equity -464.9m + L.T.Debt 10.18b))
RoIC = 15.92% (NOPAT 1.54b / Invested Capital 9.68b)
WACC = 3.25% (E(9.63b)/V(24.68b) * Re(7.35%) + D(15.05b)/V(24.68b) * Rd(0.78%) * (1-Tc(0.20)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -2.56%
[DCF Debug] Terminal Value 86.37% ; FCFF base≈1.37b ; Y1≈1.38b ; Y5≈1.47b
Fair Price DCF = 417.8 (EV 43.79b - Net Debt 14.29b = Equity 29.50b / Shares 70.6m; r=5.90% [WACC]; 5y FCF grow -0.16% → 2.90% )
EPS Correlation: 63.88 | EPS CAGR: 22.06% | SUE: 1.02 | # QB: 1
Revenue Correlation: 95.69 | Revenue CAGR: 6.91% | SUE: 2.87 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.47 | Chg30d=+0.008 | Revisions Net=+3 | Analysts=2
EPS current Year (2026-12-31): EPS=13.83 | Chg30d=+1.079 | Revisions Net=-1 | Growth EPS=+28.3% | Growth Revenue=+2.9%
EPS next Year (2027-12-31): EPS=15.72 | Chg30d=+0.793 | Revisions Net=+0 | Growth EPS=+13.7% | Growth Revenue=+3.5%